Staniforth D H, Smith R A, Hibbs M
Eur J Clin Pharmacol. 1983;24(6):751-6. doi: 10.1007/BF00607082.
A new fibrinolytic agent, BRL 26921, a member of the novel class of thrombolytic agents; the acyl enzymes, has been compared with streptokinase. It has been shown that this new agent, which can bind to fibrin before releasing activator, does not result in clinically significant destruction of the haemostatic system when compared to an equivalent dose of streptokinase.
一种新型纤溶药物BRL 26921，属于新型溶栓药物——酰基酶类，已与链激酶进行了比较。结果表明，这种新型药物在释放激活剂之前能够与纤维蛋白结合，与等量的链激酶相比，不会导致止血系统发生具有临床意义的破坏。
